U.S. FDA Head Says Chinese Heparin Contaminated On Purpose
This article was originally published in PharmAsia News
The head of the U.S. FDA says the agency suspects the heparin blood thinner supplied by Chinese companies was contaminated intentionally in a case of fraud. Commissioner Andrew von Eschenbach told an audience the heparin at fault for U.S. deaths contained oversulfated chondroitin sulfate, a version of a dietary supplement. "It was apparently done, we suspect, by virtue of economic fraud," he said, without elaboration. Other FDA officials have said it is cheaper to make heparin that way because the contaminate version is chemically similar to heparin's active ingredient, made from pig intestines. (Click here for more - a subscription may be required
You may also be interested in...
FDA may begin to rely on foreign government oversight of manufacturing even if the standards for the overseas regulators do not exactly match those in the U.S
As the agency struggles to adapt to globalization of the pharmaceutical supply chain, exact harmonization of regulatory standards may not be a goal worth pursuing.
SHANGHAI - China's State SFDA will implement an electronic ID-based drug-tracking system this year, the drug watchdog announced at a monthly press conference April 8